ScripLundbeck’s transformation under CEO Charl van Zyl continues apace and the CNS-focused Danish drugmaker has raised its full-year guidance after posting a strong set of financials for the first quarter.
In VivoAmid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van Zy
In VivoBiopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr
ScripH. Lundbeck is squarely focused on central nervous system disorders, arguably one of the most challenging areas of drug development, but the small specialty pharma is showing that investments in the t